Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06019468 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Treatment For Locally Advanced Thymic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 8, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 30, 2025 to Sep 30, 2026
    • Start date: Sep 4, 2023 to Nov 4, 2023
    • Study completion date: Dec 30, 2025 to Dec 30, 2026
    v4
  2. Start date changed from estimate of Sep 20, 2023 to Sep 4, 2023v3
  3. Study description expanded, about 1 wordv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations for the establishment of unified evaluation criteria for the neoadjuvant therapy of thymic cancer by evaluating the pathological remission status of thymic cancer specimens after neoadjuvant treatment.
Trial Details
NCT Number NCT06019468
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Conditions
(from sponsor)		 Thymic Carcinoma
Related terms Thymoma
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov